Oncologists' agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2-early breast cancer

被引：0
|
作者：
Castro-Henriques, M. [1 ]
Casadevall Aguilar, D. [2 ]
Monzonis, X. [2 ]
Martinez-Garcia, M. [2 ]
Martos, T. [2 ]
Corbera, A. [2 ]
Trias Bes, I. Tusquets [2 ]
Albanell, J. [2 ]
Servitja, S. [2 ]
机构：
[1] HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Barcelona, Spain
[2] Hosp del Mar, Med Oncol Dept, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
186P
引用
收藏
页码：S317 / S317
页数：1
相关论文
共 50 条
  • [31] Multimodal recurrence risk prediction model for HR+/HER2-early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features
    Wu, Xiaoyan
    Li, Yiman
    Chen, Jilong
    Chen, Jie
    Zhang, Wenchuan
    Lu, Xunxi
    Zhong, Xiaorong
    Zhu, Min
    Yi, Yuhao
    Bu, Hong
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [32] Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay
    Jeanette Muniz
    Kelley M. Kidwell
    N. Lynn Henry
    Breast Cancer Research and Treatment, 2016, 157 : 597 - 603
  • [33] Multimodal Recurrence Risk Prediction Model for HR+/HER2-Early Breast Cancer Following Adjuvant Chemo-Endocrine Therapy: Integrating Pathology Image and Clinicalpathological Features
    Wu, Xiaoyan
    Zhang, Wenchuan
    Lu, Xunxi
    Yi, Yuhao
    Bu, Hong
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [34] The use of Ki67 testing and scoring in HR+, HER2-early breast cancer
    Brown, J.
    Scardo, S.
    Method, M.
    Schlauch, D.
    Misch, A.
    Picard, S.
    Hamilton, E. P.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S315 - S315
  • [35] 21-gene recurrence score® in patients with primary metastatic ER+HER2-breast cancer
    Barinoff, J.
    Anastasiadou, L.
    Brandi, C.
    Junker-Stein, A.
    Silbermann, J.
    Langenfeld, M.
    Fortmann, C.
    Thill, M.
    CANCER RESEARCH, 2017, 77
  • [36] The Relationship between Recurrence Score of 21-Gene Assay and Clinicopathological Factors of Breast Cancer
    Woolf, K.
    Wang, J.
    Hicks, D. G.
    Wang, X.
    Shciffhauer, L. M.
    Skinner, K.
    Tang, P.
    LABORATORY INVESTIGATION, 2010, 90 : 79A - 79A
  • [37] Adjuvant therapy for HR+/HER2-early-stage breast cancer (EBC): Changes in practice patterns among community oncologists in Brazil
    Goncalves, Aline Coelho
    Cruz, Heloisa
    Mano, Max S.
    Ferrari, Bruno Lemos
    Ferreira, Carlos G. M.
    Andrade de Resende, Cristiano Augusto
    Bretas, Gustavo
    Reinert, Tomas
    Costa e Silva, Matheus
    Paes, Rafael
    Correia e Silva, Guilherme Munhoz
    Canedo, Jorge Alexandre
    Martins, Erika
    Aguiar, Pedro N., Jr.
    Koyama, Fernanda Christtanini
    Dienstmann, Rodrigo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Recurrence Score of 21-Gene Assay Is Correlated with a Panel of Immunopathological Factors of Breast Cancer
    Subik, K.
    Delaney, A.
    Wang, J.
    Wang, X.
    Schiffhaner, L. M.
    Shayne, M.
    Huston, A.
    Skinner, K.
    Hicks, D. G.
    Tang, P.
    LABORATORY INVESTIGATION, 2010, 90 : 74A - 74A
  • [39] The Relationship between Recurrence Score of 21-Gene Assay and Clinicopathological Factors of Breast Cancer
    Woolf, K.
    Wang, J.
    Hicks, D. G.
    Wang, X.
    Schiffhauer, L. M.
    Skinner, K.
    Tang, P.
    MODERN PATHOLOGY, 2010, 23 : 79A - 79A
  • [40] Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2-Breast Cancer
    Bottosso, Michele
    Miglietta, Federica
    Vernaci, Grazia Maria
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Griguolo, Gaia
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2884 - 2894
12345